Kyle Faget Interview Highlighted in Digital Health Regulations Year in Review
December 6, 2022
MedTech Insight
Foley & Lardner LLP Partner Kyle Faget’s October interview with MedTech Insight is highlighted in their article, “Digital Health Regulations: A Year in Review,” which summarizes both the changes in digital health regulations in 2022 and what medical devices companies should look out for in the coming year.
Faget commented on the impact of the U.S. Food and Drug Administration’s (FDA) Clinical Decision Support Software (CDS) document, saying that some companies had to reevaluate whether their CDS products qualified as a device under the new guidance as the FDA took a broader approach to regulating that what was in its jurisdiction.
To read more about Faget’s earlier comments on this topic, click here.
People
Related News
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 5, 2025
In the News
Michael Bennett and Zack Flagel Explore Pro Tennis Antitrust Battle
Foley & Lardner LLP attorneys Michael Bennett and Zack Flagel assess the antitrust litigation embroiling professional tennis in their LawInSport article, "Break(ing) Point? The Antitrust Battle that Could Transform Professional Tennis."
June 4, 2025
In the News
Foley Attorneys Explore IP Considerations for AI-Generated Logos
Foley & Lardner LLP attorneys Von Bryant, Norm Rich, and Alex Liederman authored the Bloomberg Law article, "AI-Generated Logos Require Careful Steps to Protect IP Rights."